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Abstract
The combination of expression patterns of AGR2 and CD10 by prostate cancer provided four 
phenotypes that correlated with clinical outcome. Based on immunophenotyping, 
CD10lowAGR2high, CD10highAGR2high, CD10lowAGR2low, and CD10highAGR2low were 
distinguished. AGR2+ tumors were associated with longer recurrence-free survival and CD10+ 
tumors with shorter recurrence-free survival. In high-stage cases, the CD10lowAGR2high 
phenotype was associated with a 9-fold higher recurrence-free survival than the 
CD10highAGR2low phenotype. The CD10highAGR2high and CD10lowAGR2low phenotypes were 
intermediate. The CD10highAGR2low phenotype was most frequent in high-grade primary tumors. 
Conversely, bone and other soft tissue metastases, and derivative xenografts, expressed more 
AGR2 and less CD10. AGR2 protein was readily detected in tumor metastases. The 
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CD10highAGR2low phenotype in primary tumors is predictive of poor outcome; however, the 
CD10lowAGR2high phenotype is more common in metastases. It appears that AGR2 has a 
protective function in primary tumors but may have a role in the distal spread of tumor cells.
Keywords
Prostate cancer; AGR2; CD10; cancer cell phenotypes; patient stratification; bone and soft tissue 
metastases; xenografts
Although prostate cancer is the most frequent cancer in men, only a minority of affected 
men die of the disease. Serum levels of prostate-specific antigen (PSA/KLK3) are widely 
used to screen men for prostate cancer. However, with a false positive rate of nearly 70% 
many unnecessary biopsies are being performed.1 Prostate cancer is histologically 
characterized by the Gleason grading system. Cases with predominantly pattern 3 tumor 
predict long-term survival, with or without active intervention. Cases with a pattern 4 or 
pattern 5 component are associated with poorer outcomes. For many patients, PSA level and 
Gleason score, in addition to post-surgery clinical staging, show relatively good 
performance in disease prognosis (the Partin nomogram - http://urology.jhu.edu/prostate/
partintables.php).2 There remain many cases where the known predictors fail. Thus, not only 
are informative biomarkers needed to detect early stage cancer with good confidence but 
also, more importantly, to identify patients whose cancer requires treatment. An early and 
reliable differentiation between patients with good vs. poor prognosis cancer could 
substantially reduce unnecessary morbidity-generating interventions for long-term survivors. 
Molecular signatures that provide objective classification will eventually enable such 
categorization of patients. In addition, such a categorization would ideally be made using 
either small biopsies or biofluids such as urine or blood.
Prostate cancer cells differentially express AGR2 (anterior gradient 2) and CD10/MME 
(membrane metallo-endopeptidase). AGR2 encodes a 19-kDa secreted protein, MME 
encodes a 100-kDa cell surface membrane protein. AGR2 expression is increased in prostate 
cancer cells (and cells of high-grade prostatic intraepithelial neoplasia, PIN) compared to the 
normal counterpart luminal epithelial cells.3-6 CD10, in contrast, is decreased in cancer 
cells, although about 30% of tumors express CD10.7-9 Tumors with CD10+ cancer cells tend 
to be more frequent in higher Gleason score cancers, and CD10+ cancer cells predominate in 
regional lymph node metastases.8-10 Conversely, AGR2+ tumors predominate in lower 
Gleason score cancers, and cancer cells of Gleason patterns 4 and 5 tend to express lower 
levels of AGR2.5,6
Expression of CD10 by prostate cancer correlates with poor disease outcome and lower rates 
of patient survival.9-11 In addition, cytoplasmic rather than membraneous localization of the 
CD10 protein in tumor cells is associated with poor outcome.11 This finding could be 
attributed to the association of CD10 with cytoplasmic heat shock proteins such HSP27 
(HSPB1) in prostate cancer cells; CD10+ luminal cells do not express HSP27.12 In contrast, 
prostate cancer expression of AGR2 correlates with longer patient survival.5 Could 
differential expression by cancer cells of CD10 and AGR2 provide more precise prognostic 
information?
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In this study, expression of AGR2 and CD10 by prostate cancer was probed in a tissue 
microarray of over 200 radical prostatectomy cases in which outcomes were known. 
Immunohistochemistry allowed us to identify different cancer cell phenotypes based on 
expression levels of these two markers. AGR2 and CD10 expression was further probed in 
tissue microarrays of bone and soft tissue metastases, and of tumor xenografts, with the 
expectation that they might reveal phenotypes linked to poor outcomes.
Materials and methods
This study is approved by our institutional review boards.
Immunohistochemical Analysis of AGR2 and CD10 Gene Expression
Tissue microarrays—The tissue microarrays of primary tumors and prostate cancer 
metastasis, LuCaP prostate cancer xenografts were constructed with cores of 0.6 mm and 1 
mm in diameter, respectively, from blocks of formalin-fixed, paraffin-embedded tissues. 
Three tissue microarrays were used: 1) primary prostate tumors (UCLA TMA) constructed 
from 246 randomly selected hormone-naïve cases treated by surgery with three 
morphologically representative biopsies of each tumor, plus matching benign tissue and 
available in situ neoplastic lesions (PIN); biochemical recurrence was the indication used for 
treatment failure;5,13 2) prostate cancer metastases (UW TMA22) procured from donor 
autopsies (i.e., representative of late-stage disease) with n=248 cores from 124 different sites 
of 23 patients; 3) the LuCaP series of prostate cancer xenografts, n=24, serially passaged in 
immune compromised mice (UW TMA46).
Tissue microarray immunohistochemistry—For analysis, 6 μm-thin sections were 
cut from each array block. Following deparaffinization and antigen retrieval (by boiling in 
0.01 M citrate buffer for 25 min), endogenous peroxidase activity was quenched and the 
sections treated with 5% goat-horse-chicken serum. Slides were incubated overnight with 
either rabbit polyclonal AGR2 antibody (ab43043, abcam, Cambridge, MA) at 1:30 or 
mouse monoclonal CD10 antibody (clone 56C6, Lab Vision, Fremont, CA) at 1:30 in 0.1% 
bovine serum albumin-phosphate buffered saline. Specific staining was detected by applying 
anti-rabbit or anti-mouse horseradish peroxidase-conjugated secondary antibody and avidin-
biotin complex followed by diaminobenzidine (Vector ABC, Burlingame, CA). As negative 
controls, tissue was incubated with concentration-matched non-immune IgG. Frozen 
sections were also prepared from OCT tissue blocks, and were stained with either 
monoclonal anti-AGR2 (clone P1G4, IgG1)14 at 1:30, or anti-CD10 (clone HI10a, IgG1, BD 
Bioscience, San Jose, CA) at 1:30.
Tissue microarray scoring for AGR2 and CD10 in primary tumors—The 
percentage of glandular cell staining was scored from 0-100% and the intensity of staining 
was rated from 0 (absent immunoreactivity) to 3 (intense). An integrated measure of 
expression for frequency and intensity of staining was calculated using the following 
formula: [3(%x)+2(%y)+1(%z)]/100, where x, y, and z represented the percentage of cells 
staining at intensity 3, 2, and 1, respectively. For outcomes analysis, a mean pooled value 
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for each case was calculated. Protein expression was correlated with disease outcome, 
clinicopathological variables,13 and recurrence following radical prostatectomy.
Statistical analysis of correlation between tumor phenotypes and outcome—
Briefly, non-parametric two-group and multi-group comparisons were carried out using 
Mann-Whitney and Kruskal-Wallis tests. Correlations were calculated using Spearman 
Correlation. Patients were dichotomized at an optimal cutpoint, and recurrence-free survival 
curves were visualized using the Kaplan-Meier method with the difference between outcome 
distributions assessed by the log-rank test. The Cox proportional hazards model was used to 
test the statistical significance of predictors in both a univariate and a multivariate setting. 
All statistical analyses were performed with StatView Version 5.0 (SAS Institute) or with 
the freely available software package, R (http://www.r-project.org).
AGR2 and CD10 in xenografts and tumor metastases—Tissue microarray 
immunohistochemistry was similarly performed for the arrays containing the LuCaP 
xenografts and metastases.
Gene Expression Analysis by Microarrays
Expression levels from array signal values—The xenografts were maintained and 
propagated in Balb/c nu/nu intact male mice, and the castration-resistant variants were 
developed from parental tumors on regrowth after castration. These were maintained and 
propagated in castrated B17 Fox Chase SCID male mice (Charles River, Wilmington, 
MA).15 The origin and characteristics of all serially passaged xenografts were described in 
ref. 16,17. None of these xenografts could be grown in vitro. Xenografts were harvested at 
100 mg size, frozen for storage, and each was processed for RNA isolation using STAT60 
(Tel-Test, Friendswood, TX).
Metastasis specimens were collected from rapid autopsies of patients who died from 
metastatic prostate cancer performed under the aegis of the IRB-approved Prostate Cancer 
Donor Program at the University of Washington Medical Center.18 Within 4 h of death, 
samples of all gross tumors and bone metastases were obtained under sterile conditions. 
Each specimen was assigned a unique laboratory research number and rapidly frozen or 
formalin fixed (bone metastases were decalcified in formic acid) and paraffin embedded. 
RNA was similarly prepared from frozen specimens using STAT60.
For array analysis, tumor (xenograft and metastasis) RNA was amplified one round and 
hybridized to Agilent 44K whole human genome expression oligonucleotide microarrays 
(Agilent Technologies, Santa Clara, CA). Probe labeling and hybridization was performed 
following the Agilent protocol, and fluorescent array images were collected using the 
Agilent DNA microarray scanner G2565BA. Agilent Feature Extraction software was used 
to grid, extract, and normalize data as reported in ref. 19.
AGR2 Protein in Metastasis
ELISA measurement of tissue digestion media—BD Falcon Flexible (Franklin 
Lakes, NJ) plates were coated with purified monoclonal antibody P1G4 (1:1,000) in 
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phosphate buffered saline overnight at 4°, rinsed 3x with phosphate buffered saline-0.05% 
Tween, blocked with 1% heat-denatured bovine serum albumin-phosphate buffered saline. 
Cell-free tissue digestion media and spent cancer cell line culture media samples were added 
for incubation at 4° overnight. Monoclonal antibody P3A5 (IgG2a, 1:1,000)14 was then 
added for 1 h at room temperature. For detection, horse radish peroxidase-conjugated anti-
mouse IgG2a was used for 30 min at room temperature. 2,2′-Azinobis[3-
ethylbenzothiazoline-6-sulfonic acid]-diammonium salt (KPL/Fisher, Belgium) was the 
chromogenic reagent for measurement at λ=405 nm. A standard curve was obtained by 
using recombinant AGR2 (GenWay Biotech, San Diego, CA) as described.14
Results
CD10 and AGR2 Expression Patterns in Primary Prostate Cancer
In a majority of prostate tumors, AGR2 expression was increased and CD10 expression 
decreased relative to luminal epithelial cells of benign glands (Figure 1). Thus, cancer cells 
were CD10−AGR2+ and luminal cells were CD10+AGR2−. In the example shown, the 
adjacent tumor and benign glands were clearly distinguished by phenotyping with these two 
markers. Faint AGR2 staining of the stroma surrounding the cancer glands could indicate 
that AGR2 was secreted. No such staining feature was seen for CD26 (DPP4), a cell surface 
antigen on luminal and cancer cells previously used in cell sorting for transcriptome 
analysis.4 This pattern of AGR2 increase and CD10 decrease was also found in the glands of 
PIN present in this tumor tissue specimen (Figure 1). In cancer cells, AGR2 staining 
intensity and DNA array expression values for AGR2 probesets4,14 indicated moderately 
abundant levels of the protein and the transcript.
Correlation between AGR2/CD10 Expression and Clinical Outcome
We have previously identified a trend of lower AGR2 expression in higher Gleason grades,5 
and a trend of more CD10-positive tumor cells in higher Gleason grades.8,9 In the present 
study, analysis of AGR2 and CD10 expression showed a correlation between the 
CD10lowAGR2high tumor phenotype and greater recurrence-free survival in high-stage 
patients (III/IV) as shown in Figure 2 [while almost all low-stage (I/II) patients were cured 
of their disease by surgery]. In contrast, patients with CD10highAGR2low tumors had the 
lowest recurrence-free rate. At about 60 months post-surgery, >80% of the 
CD10lowAGR2high patients showed no recurrence, whereas only <30% of the 
CD10highAGR2low patients did (P=0.0247). Patients with CD10highAGR2high and 
CD10lowAGR2low tumors showed intermediate rates. Thus, for high-stage patients whose 
overall survival was relatively poor, a small group of men with CD10lowAGR2high tumors 
still experienced a favorable outcome.
High CD10 and low AGR2 expression might be the basis of high disease stage as indicated 
by the relative percentages of these phenotypes. There were six cases of CD10lowAGR2high 
(10%), 13 cases of CD10highAGR2high (21%), 8 cases of CD10lowAGR2low (13%), and 36 
cases of CD10highAGR2low (57%) in this patient subgrouping. Over half of the high-stage 
patients contained CD10highAGR2low cancer cells in their tumor, whereas only 10% 
contained CD10lowAGR2high cancer cells in their tumor. Examples of specimens staining 
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for CD10 and AGR2 are shown in Figure 3 for the four phenotypes CD10+AGR2+, 
CD10−AGR2+, CD10+AGR2−, CD10−AGR2−. Note the first three cases all showed 
glandular differentiation (i.e., Gleason pattern 3) yet the outcome would be different due to 
their different AGR2/CD10 phenotyping.
Table 1 shows the dataset of the tissue microarray cases in pairwise comparison (A grouping 
vs. B grouping). cRR was the current hazard ratio between individual A and B groupings 
where cRR<1 if A showed higher survival and >1 if B showed higher survival. In row 1, the 
CD10lowAGR2high group showed higher survival by 5-fold than the CD10lowAGR2low 
group. This indicated that tumor expression of AGR2 had perhaps a protective effect. In row 
5, the CD10highAGR2low group showed lower survival by 9-fold than the 
CD10lowAGR2high group with the largest observed difference. This indicated that tumor 
expression of CD10 had a deleterious effect.
AGR2 and CD10 Expression in Metastases
Based on the above findings in primary tumors, one would expect the CD10highAGR2low 
phenotype to be predominant in metastases of distal organs. Figure 4 shows 
immunoreactivity of selected bone/soft tissue metastases. Examples of AGR2/CD10 
phenotypes included CD10lowAGR2high 05-116E2 liver, CD10lowAGR2high 05-116F2 lung, 
CD10−AGR2high 06-047H2 iliac lymph node, CD10−AGR2− 05-144G1 retroperitoneal 
lymph node, CD10−AGR2− 03-192A3 liver, CD10−AGR2+ 99-064DD1 L4 vertebra, 
CD10−AGR2+ 05-214DD4 sacrum, CD10lowAGR2high 05-011F3 liver, CD10−AGR2+ 
04-050DD3 sacrum, CD10−AGR2− 03-082H2 liver. The tumors showed a range of 
expression levels (hence the “high” or “low” indication) and the staining was cytoplasmic 
for AGR2. Of these, only 3/10 showed no AGR2 expression while 7/10 showed no CD10 
expression. The AGR2-negative tumors were all small cell carcinoma: 05-144G1, 
03-192A3, 03-082H2; plus 05-144EE1 shown in Figure 5. The AGR2 pattern in metastases 
was corroborated by DNA microarray analysis (Figure 5). For example, the stronger overall 
AGR2 staining of 00-140FF than 07-050EE1 was reflected in the DNA microarray signal 
values. CD10 expression was also confirmed, and the small cell carcinoma samples showed 
low values for CD10 (05-144EE2, a sister sampling to 05-144EE1, Figure 5). Thus, the 
predominant cancer cell phenotype in distal metastasis was not CD10highAGR2low but rather 
CD10low/−AGR2high. Note that the metastasis samples were obtained from patients likely 
treated by androgen ablation and other types of therapy, whereas the primary cancer samples 
were from patients treated by surgery only.
AGR2 Protein in Metastasis Tissue
Testing of tissue collagenase digestion media by ELISA further supported the AGR2 data. 
For reference, AGR2 protein in the culture media of cell lines C4-2, C4-2B, CL1 and PC3 
was used (Figure 6). C4-2 was negative for AGR2; a small amount was detected in C4-2B; 
high amounts in PC3 and CL1.14 For multiple metastasis specimens, AGR2 was detected 
(Figure 6). The specimens were obtained from both donor autopsies and surgical procedures 
(98-378 bone and 00-061 node).
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AGR2 and CD10 Expression in Prostate Cancer Cell Lines and Xenografts
Figure 7 shows the RNA expression levels of AGR2 and CD10 in cancer cell lines and 
xenografts. Luminal epithelial cells (L), Gleason pattern 3 (G3) and Gleason pattern 4 (G4) 
cancer cells of primary tumors (ref. 4) were also shown. C4-2 and CL1 were both derived 
from LNCaP by androgen manipulation. LuCaP 35 is similar to LNCaP in gene expression; 
both were established from positive lymph nodes.20 LuCaP 49, characterized by minimal 
AGR2 and CD10 expression, is representative of small cell carcinoma.21 Among them, 
these phenotypes were found – CD10−AGR2+ G3 cancer, CL1, PC3; CD10highAGR2low 
LuCaP 35; CD10−AGR2low G4 cancer; CD10+AGR2− LNCaP, C4-2; CD10−AGR2− 
DU145, LuCaP 49. It appeared that cancer cell lines considered to be more aggressive, PC3 
and CL1, showed increased AGR2 and decreased CD10 expression. This was not the case 
for G3 vs. G4 cells of primary tumors where lower levels of AGR2 were found in the 
potentially more aggressive G4 cells.
Figure 8 shows immunostains of LuCaP xenografts (Table 2) harvested from subcutaneous 
tumors passaged in mice. The AGR2/CD10 phenotypes were: CD10lowAGR2high LuCaP 
23.12 (established from a liver metastasis), LuCaP 105 (rib); CD10highAGR2low LuCaP 141 
(transurethral resection of the prostate), LuCaP 86.2 (bladder); CD10lowAGR2low LuCaP 81 
(lymph node); CD10−AGR2− LuCaP 145.1 (liver). LuCaP 145.1 was representative of small 
cell carcinoma, and like LuCaP 49 (and LuCaP 93, LuCaP 145.2), was negative for both 
markers. LuCaP 141, established from a surgical specimen of primary cancer, and LuCaP 
86.2, from a resected bladder metastasis, expressed CD10. Protein expression was 
corroborated by DNA microarray analysis of these xenografts (Figure 9).
LuCaP 35CR, LuCaP 96CR, LuCaP 23.1CR (CR=castration resistant) provided a means to 
examine the effect of androgen ablation on the expression of AGR2 and CD10. Based on 
immunostaining, the phenotypes were CD10−AGR2− for LuCaP 23.1, CD10highAGR2low 
for LuCaP 35, CD10lowAGR2high for LuCaP 96. It is unclear why the DNA microarray 
results for LuCaP 23.1 and LuCaP 96 were discordant with immunostaining (Figure 9). 
Androgen removal appeared to reduce overall staining of CD10 in LuCaP 96CR (Figure 10). 
DNA array analysis also showed a decrease in LuCaP 96CR (Figure 9). For AGR2, some 
weak focal staining in LuCaP 23.1CR, and strong staining between tumor cells in LuCaP 
96CR was detected (Figure 10). These results were akin to that in the derivation of 
CD10+AGR2− C4-2 from CD10+AGR2− LNCaP in castrated animals. Since the LuCaP 
tumors cannot be cultured in vitro, a similar pathway (i.e., long-term growth in androgen-
free media) to obtain CD10−AGR2+ CL1 from LNCaP could not be duplicated.
Discussion
AGR2 and CD10 are both biomarkers for prostate cancer. AGR2 expression is lower in 
cancer cells of higher grades whereas CD10-positive cancer cells are more frequent in 
higher grade cancers. A small subset of tumors with similar Gleason pattern show 
differential AGR2/CD10 expression, therefore, AGR2/CD10 phenotyping would perhaps be 
more useful than Gleason scoring in predicting outcome. AGR2 appears to be protective 
while CD10 imparts a more aggressive potential in prostate cancer. Thus, even for high-
stage patients where overall survival is poor, tumors showing high AGR2 and low CD10 
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expression would still predict a better outcome. While both AGR2 and CD10 are 
independently prognostic, in combination, three phenotypes define recurrence probability 
from low to high: CD10lowAGR2high < CD10highAGR2high = CD10lowAGR2low < 
CD10highAGR2low. The precise molecular functioning of the two proteins in cancer cells is 
unknown. Note the luminal cell CD10+AGR2− phenotype corresponds to the aggressive 
CD10highAGR2low cancer type. The action of these gene products are likely dependent on 
cell context. Similarly, although G3 cancer and CL1 shared a common phenotype in AGR2 
and CD10, their overall gene expression is very different.20
The expression pattern of AGR2 and CD10 in distal metastases of the bone and soft tissues 
appears at odds with that in primary tumors where potential of cancer spread is correlated 
with Gleason grade. The majority of these metastases are typed CD10lowAGR2high whereas 
this phenotype predominates in Gleason 3. Instead, the CD10highAGR2low phenotype in 
primary tumors is correlated with poor outcome. Most regional lymph node metastases 
contain CD10+AGR2−/+ tumor cells. For example, CD10+AGR2− LNCaP and 
CD10+AGR2+ LuCaP 35 are both derived from node metastasis. Outside their metastasis 
potential, the transcriptomes of LNCaP and LuCaP 35 are similar to that of CD10+AGR2− 
luminal cells and CD10−AGR2+ G3 cancer cells.20 Additionally, LuCaP 86.2, established 
from a surgically resected bladder metastasis (representative of local spread), is CD10high. 
This suggests that CD10+ tumor cells are more likely to escape the prostate than CD10− 
ones. For distal spread, the functional role of AGR2 becomes more important whereas that 
of CD10 becomes less important. This hypothesis could explain the expression pattern seen 
in bone and other organ metastases, which is in line with the experimental data showing 
AGR2 promoted tumor cell growth and dissemination.22-26 What, then, could cause the 
phenotypic change to CD10−AGR2+ from escaped CD10+AGR2− tumor cells? One possible 
mechanism involves physiological stress such as serum depletion or oxygen starvation on 
cancer cell AGR2 expression.27 Hormone ablation is a physiological stress for prostate 
cancer cells. The LNCaP cell line was grown in androgen-free media to obtain the androgen 
independent variant CL1.28 CL1 expresses AGR2 at a high level. LNCaP was also grown in 
castrated mice with human bone stromal cells to obtain C4-2, and C4-2 was further selected 
for growth in bone to obtain C4-2B.29 While C4-2 remains CD10+AGR2−, C4-2B produces 
a small amount of AGR2. PC3, established from a bone metastasis,30 is AGR2+. With the 
gain of AGR2 expression, the CL1 cells have also lost CD10 expression.31 In the castration 
resistant LuCaP variants, some weak staining of AGR2 is present in LuCaP 23.1CR vs. 
complete absent staining in LuCaP 23.1; a decrease in overall CD10 staining is seen in 
LuCaP 96CR vs. LuCaP 96. This complex expression pattern of CD10 and AGR2 in 
prostate cancer could explain discrepant conclusions reported in the literature regarding their 
prognostic value: CD10 expression was correlated with better outcome;7 AGR2 expression 
was correlated with poorer outcome.32 A similar situation may exist for AGR2 in breast 
cancer where expression is correlated with poor survival by one study33 vs. that with better 
survival by another.34 In the latter case, AGR2 expression is associated breast cancer 
differentiation and lower tumor grade as in prostate cancer.
Our working hypothesis is that CD10 and AGR2 have opposing functions in prostate cancer 
cells. Luminal CD10 expression is lost and AGR2 expression is gained early in cancer 
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development. Certain cancer cells regain CD10 expression (or retain luminal CD10 
expression) with or without decrease in AGR2 expression in progression from low to high 
Gleason grade. CD10 allows the cancer cells to escape the prostate to regional lymph nodes 
and proximal organs like the bladder. In order for distal spread to organs like bone, the 
cancer cells require functional AGR2. This hypothesis is supported by the result showing 
that a surgically removed bone lesion, specimen 98-378, was AGR2 positive, and by the fact 
that CL1 cells are highly metastatic in mice whereas LNCaP cells are not.28 The LNCaP to 
CL1 pathway suggests that AGR2 expression could be triggered by a physiological stress 
such as androgen ablation used in the treatment of post-operative patients with rising PSA.
In summary, the prostate cancer biomarkers, AGR2 and CD10, can be used in combination 
to stratify prostate cancer patients for clinical outcome. Patients with CD10highAGR2low 
tumors would appear to fare worse than those with CD10lowAGR2high tumors. However, 
cancer cells in distal metastases of advanced disease are CD10lowAGR2high.
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Figure 1. 
AGR2 and CD10 expression in prostate cancer. Top: tumor glands in specimen 99-010D are 
AGR2+CD10−CD26+, whereas benign glands are AGR2−CD10+CD26+. Bottom: PIN 
glands in 99-010D show the same phenotype as cancer glands. Magnification 100x.
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Figure 2. 
Cancer progression. The Kaplan-Meier plot shows the outcome of high-stage patients 
grouped by CD10 and AGR2 expression. At 5 years, 85% of CD10lowAGR2high were 
recurrence-free compared to just 25% of CD10highAGR2low.
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Figure 3. 
Primary cancer cell phenotypes. Shown are examples of the four different cancer cell 
phenotypes based on CD10 and AGR2 immunostaining. Magnification 100x.
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Figure 4. 
Metastasis phenotypes. Shown are four representative tissue microarray sections of bone and 
soft tissue metastases, identified by case numbers, stained for AGR2 and CD10. Their 
AGR2/CD10 phenotypes are indicated. All four show strong AGR2 reactivity, while only 
two show moderate to weak CD10 reactivity. Magnification is 40x.
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Figure 5. 
AGR2 and CD10 RNA expression levels. Shown are AGR2 staining of 07-050EE1 (top 
section: top two panels magnification 100x and bottom left magnification 200x) and 
00-1140FF (top section: bottom right magnification 100x). AGR2 staining is cytoplasmic. 
Small cell carcinoma in 05-144EE2 (middle section) is negative for AGR2 (left 
magnification 100x, right magnification 200x). DNA array analysis data of metastases 
(bottom section) are shown with arrows over the three immunostained specimens shown in 
the Figure. Increased AGR2 expression is denoted by the high CY3 intensity values (red 
arrows: 27870 and 65828) and decreased expression by values (black arrow: 1297). Note the 
generally lower CY3 intensity values for CD10.
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Figure 6. 
Quantitative measurement of AGR2 in tissue. The metastasis specimens (* to indicate from 
surgery not autopsy) identified on the x-axis were minced and digested by collagenase in 
culture media overnight, and the cell-free media supernatant was assayed by AGR2 ELISA. 
OD405 readings are indicated on the y-axis. The line indicates the level obtained with buffer/
media only. Levels in culture supernatant of C4-2, C4-2B, PC3 and CL1 are included for 
comparison.
Ho et al. Page 17
Mod Pathol. Author manuscript; available in PMC 2013 December 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 7. 
Cancer cell AGR2/CD10 RNA expression levels. Levels were determined through DNA 
microarray analysis with signal intensity values on the y-axis. Indicated on the x-axis are G3 
and G4 primary tumor cell types, L luminal, LNCaP, C4-2, CL1, DU145, PC3 cell lines, 
LuCaP35, LuCaP 49 xenografts. Except for DU145 and LuCaP 49, the expression pattern is 
either CD10 or AGR2.
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Figure 8. 
LuCaP phenotypes. Staining results for six LuCaP xenografts and their AGR2/CD10 
phenotypes are shown, magnification 40x. Where staining is absent a “−“ sign is used, or 
present a ”+” sign is used. “High” or “low” are used to indicate strong or weak staining.
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Figure 9. 
Expression levels of AGR2 and CD10 in xenografts. As inferred from DNA microarray 
analysis, these levels are presented in histogram format (top). CY3 intensity values are 
indicated on the y-axis. Because of the lower values for CD10, a separate histogram for 
CD10 is included (bottom). Note the ~6-fold decrease in CD10 from LuCaP 96 to LuCaP 
96CR.
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Figure 10. 
Castration resistant LuCaP xenografts. Staining between LuCaP 23.1 and LuCaP 23.1CR for 
AGR2, between LuCaP 96 and LuCaP 96CR for AGR2 and CD10 are shown, magnification 
200x. Red arrows in the LuCaP23.1CR AGR2 panel show examples of weak cytoplasmic 
staining of tumor cells. The white arrow in the LuCaP 96CR AGR2 panel shows 
intercellular AGR2 reactivity. Note the overall decreased CD10 staining in the LuCaP 96CR 
CD10 panel than in the LuCaP 96 CD10 panel.
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